C compiler, LustreC, into a generator of both executable code and associated specification. Model-based design tools are ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Interesting Engineering on MSN
AI uncovers 360,000 DNA knots that quietly shape how genes turn on and off
AI maps fleeting DNA quadruplexes, revealing paired structures that control genes in healthy cells and cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback